Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback